TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02778828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: adjustment of Linezolid of based on the AUC/MIC and % T\> MIC for each patient to confirm the appropriateness, in light of the peak and residual, and the interest of the split doses more frequently performed in case of too low residual or toxicity.
Study: NCT02446327

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling for biomarker assessment
Study: NCT02501434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous Low-Dose IV Unfractionated Heparin Infusion
Description: Continuous intravenous infusion of a low-dose unfractionated heparin drip
Study: NCT03639558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol + Promethazine + Chlorpromazine
Description: This is the usual treatment given by this hospital during an aggressive psychiatric episode.
Study: NCT03063879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg and daclatasvir 60 mg
Description: Daily fixed dose combination pill (Sovodak) containing 400 mg sofosbuvir and 60 mg daclatasvir for 12 weeks if not cirrhotic (liver stiffness \< 12 KPa) or 24 weeks if cirrhotic
Study: NCT01914055

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: angio-guided thrombus aspiration (Eliminate catheter, Terumo, Tokyo, Japan)
Description: angio-guided thrombus aspiration with monorail thrombus aspiration catheter (Eliminate, Terumo, Tokyo, Japan)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT-guided thrombus aspiration (Eliminate catheter, Terumo, Tokyo, Japan)
Description: FD-OCT-guided thrombus aspiration with monorail thrombus aspiration catheter (Eliminate, Terumo, Tokyo, Japan); OCT images will be acquired at the site of culprit coronary artery with a commercially available system (Lunawave System; Fastview catheter/Terumo, Tokio, Japan OR C7 System; LightLab Imaging Inc; C7 Dragonfly catheter/St Jude Medical, Westford, MA)
Study: NCT03306953

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectus muscle approximation
Description: The surgeon will take sutures to approximate rectus muscles at the end of cesarean delivery.
Study: NCT02791893

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: VNS device
Description: Hand held device to use for self administration of vagus nerve stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VNS device
Description: Hand held device to use for self administration of vagus nerve stimulation.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Inactive device
Description: Hand held device to use for self administration of simulated vagus nerve stimulation.
Study: NCT02109510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonintubated sedation anesthesia with dexmedetomidine IV, ketamine IV and intercostal nerve block with lidocaine infiltration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intubated general anesthesia with propofol IV, rocuronium IV ,sevoflurane and N2O gas

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single port thoracoscopic bullectomy
Description: Thoracoscopic bullae resection with automated stapler through the single incision (2.0 cm length) at 5th intercostal space.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single port thoracoscopic bullectomy
Description: Thoracoscopic bullae resection with automated stapler through the single incision (2.0 cm length) at 5th intercostal space.
Study: NCT01616953

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixmyelocel-T
Description: Twelve days after the bone marrow aspiration, alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with the cell therapy (Ixmyelocel-T)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous Bone Grafting
Description: Alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with an autogenous bone block harvested from an intraoral or extraoral site, according to standard of care.
Study: NCT05055895

Intervention type: DRUG
Intervention: Anticholinergic burden
Description: The anticholinergic burden (ACB) was assessed using the Anticholinergic Burden Scale.~Higher ACB was described as equal or higher than 1.

Intervention type: DRUG
Intervention: Anticholinergic burden
Description: The anticholinergic burden (ACB) was assessed using the Anticholinergic Burden Scale.~Higher ACB was described as equal or higher than 1.
Study: NCT03466359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DEF-EI : Energy restriction induced energy deficit
Description: DEF-EI : Energy restriction induced energy deficit The content of their energy intake will be decreased by 10% daily compared with the phase one of the protocol (stabilization of intake). This decrease will be allowed by the internship nature of the clinical program; all the meals are prepared and served by the personal of the clinical centre.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DEF-EX : Exercise induced energy deficit
Description: DEF-EX : Exercise induced energy deficit While their intake will remain the same as phase 1, they will increase their physical activity energy expenditure by 10% thanks to an increase of their prescribed exercise intensities or durations.
Study: NCT01833091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: artificial night
Description: Infants in the intervention group received light cyclic with pattern 12 hours. Light period was from 7 to 19 during which the infants were put in the normal environmental light and dark period was from 19 to 7 during which was the infants' incubator was covered with linen cloth. The vital signsand \& arterial oxygen saturation of the infants in the intervention group were controlled before covering the incubator i.e. at 19. Also, the infant's vital signs were again monitored at 7 am.The infant weighed in every day at 7 am during the 10 days of study. Feeding tolerance was daily determined at 8 am, using nasogastric tube or orogastric tube to control residue as well as to review the presence or absence of abdominal distention, vomiting.
Study: NCT04219683

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mandibular vertical height augmentation in segmental defects using combined vascularized and non-vascularized fibula flap
Description: Using Free Fibula Flap for reconstruction of mandibular segemental defect
Study: NCT03639558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol + Promethazine
Description: This is the second most used psycho-pharmacological combination used in this hospital during an aggressive psychiatric episode.
Study: NCT01669473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EHR Based Strategy to promote Safe and Appropriate Drug Use
Description: The printed tools presented in the intervention include:~1. Medication Review: a consolidated list of the medications a patient is currently taking.~2. Medication Sheet: a medication information sheet, including simplified prescription instructions, for each medication that a patient is newly prescribed.~3. Medication List: a table that lists all medications taken by the patient and provides an orientation on how to best organize and simplify their medication regimen
Study: NCT01621191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Administered Orally
Study: NCT01046799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir monotherapy after short-term HBIg therapy for patients transplanted for hepatitis B induced end-stage liver disease; in case of prior lamivudine treatment, tenofovir will be added to the reinfection prophylaxis
Study: NCT01286389

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: medical care
Description: Conventional medical care, geriatric consultations at least 6 times in 12 months, short lifestyle counseling (exercise+healthy diet)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical care
Description: Conventional medical care, geriatric consultations at least 6 times in 12 months, short lifestyle counseling (exercise+healthy diet)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: caloric restriction
Description: Nutritional guidance: through at least 2 individual assistance and group sessions, lasting 1 hour, weekly for 4 months, and biweekly for 2 months and monthly thereafter (26-28 meetings/1year).The diet plan will recommend a deficit from 500 to 750 kcal/day in order to promote loss of about 0.5kg/week, containing 1g/kg of protein per day (minimum 1200kcal/day), high in fiber, vegetables and whole foods. The goal of weight loss will be 10% of initial weight. Group activities consist of lectures on nutrition education, food composition and its importance to health, food preparation techniques, self-monitoring weight, eating behavior and count calories.
Study: NCT04686656

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nasal oxygen
Description: Nasal cannula will be placed by the anesthesiologist. 6 l/ min of supplemental oxygen will be administered with nasal cannula.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: buccal oxygen
Description: Ring-adair-elwyn (RAE) tube will be placed by the anesthesiologist. 6 l/ min of supplemental oxygen will be administered with RAE tube.
Study: NCT02766426

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle change program
Description: Women attended a multidisciplinary counseling (by both the dietitian and the gynecologist). They were given nutritional advice about lifestyle and physical activity, in agreement with the Italian Guidelines for a healthy diet during pregnancy. The diet given comprised 1500 kcal/day and consisted of 3 main meals and 3 snacks (breakfast, snack, lunch, snack, dinner, and evening snack) that corresponds to the baseline metabolism of a pregnant woman. In view of the physical activity program, the dietitian added an amount of 200 kcal/day for obese or 300 kcal/day for overweight women.~The exercise intervention was focused on increasing walking and developing a more active lifestyle. The recommendation for physical activity was to perform 30 min of moderate intensity activity at least 3 days a week.
Study: NCT03465917

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Renal Denervation
Description: Bilateral denervation of the renal arteries using extravascular administration of neurolytic alcohol
Study: NCT02758990

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Axon Eyewear
Description: Subjects will be asked to utilize the therapeutic eyewear when exposed to bright or fluorescent light.
Study: NCT01657370

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue medication
Description: If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,~Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\]), anti-emetics, triptans, opiates or other medication not explicitly excluded.
Study: NCT03092310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas Device
Description: Artificial Pancreas Device
Study: NCT02758990

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Axon Eyewear
Description: Subjects will be asked to utilize the therapeutic eyewear when exposed to bright or fluorescent light.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chocolate
Description: Subjects will be asked to increase chocolate intake by eating 57g per day.
Study: NCT01146665

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based PAF
Description: This intervention includes standard medical care followed by receipt of computer-based Personalized Assessment Feedback (PAF). PAF is a type of brief intervention that targets norm misperceptions, for example summarizing a person's drinking in comparison to the average male or female in the general population. Theoretically, such normative feedback corrects norm misperceptions and motivates drinkers to re-evaluate their consumption patterns.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Computer-based Sham
Description: This intervention includes standard medical care followed by receipt of a computer-based sham. The sham is similar in format and duration as the computer-based Personalized Assessment Feedback but will engage youth in nutrition and exercise-related questions.
Study: NCT02527005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulphadoxine-pyrimethamine
Description: Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets monthly for 3 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulphadoxine-pyrimethamine
Description: Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets monthly for 3 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Tabs Azithromycin 500mg daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Tabs Azithromycin 500mg daily for 3 days
Study: NCT02013609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Treatment 12 weeks) - Up to 3 mg/day, once daily dose, tablets, orally
Study: NCT01135225

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PROMUS(TM) Element (TM) Stent System
Description: The PROMUS Element Everolimus-Eluting Coronary Stent System is a device/drug combination product composed of two components: a device (coronary stent system) and a drug product (a formulation of everolimus contained in a polymer coating.
Study: NCT00880997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin
Description: Medication induction occurred at a rate of 2mg/week until 8mg/day target dose was achieved as follows:~1. Dox-Fast Group: Defined as participants reaching the target dose after a 4-week titration period. Participants were stabilized on doxazosin or placebo over weeks 4-13 (for Dox-Fast group)~2. Dox-Slow Group: Defined as participants reaching the target dose after an 8-week titration period. Participants were stabilized on doxazosin or placebo over weeks 8-13 (for Dox-Slow group)~Both doxazosin groups will be tapered off doxazosin or placebo over study weeks 14-17.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be administered a sugar pill to mimic the doxazosin active medication with administration being the same as the active medication.
Study: NCT05494931

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: corneal neurotomy
Description: Classic Gunderson conjunctival flap surgery adjuncted by corneal neurotomy
Study: NCT00522951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Description: Gadobutrol enhanced MRI (first injection of gadobutrol 0.1 mmol/kg bw, corresponding to a dose of 0.1 mmol/kg bw)
Study: NCT01135225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evolution Stent System
Description: The Evolution Everolimus-Eluting Monorail Coronary Stent System is a device/drug combination comprised of two regulated components: a device (coronary stent stent) and a drug product (a formulation of everolimus contained in a biodegradable polymer coating).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evolution Stent System
Description: The Evolution Everolimus-Eluting Monorail Coronary Stent System is a device/drug combination comprised of two regulated components: a device (coronary stent stent) and a drug product (a formulation of everolimus contained in a biodegradable polymer coating).
Study: NCT03816787

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Negative pressure therapy
Description: Participants assigned to the treatment group will receive wet-cupping therapy 1 times per week for 4 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Negative pressure therapy
Description: Participants assigned to the treatment group will receive wet-cupping therapy 1 times per week for 4 weeks
Study: NCT02159261

Intervention type: DRUG
Intervention: BAY98-7071_EE20/DRSP/L-5-MTHF
Description: Patients treated by Physicians under approved local prescriptions
Study: NCT03495817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-50002
Description: ATI-50002 Topical Solution
Study: NCT00635115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a new generation of corrective lens for presbyopia (i.e., Varilux Panamic Orma Crizal)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: an old generation of corrective lens for presbyopia (i.e., Varilux Comfort Orma Crizal)
Study: NCT01543659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-huJ591
Description: The first 10 patients enrolled in the study will undergo serial whole-body scans to allow assessment of 89Zr-DFO-huJ591 biodistribution. There will be no intervening changes in therapy between the scans. The first 10 patients enrolled will also have serial blood samples drawn for PK analysis (2 -3 mL per time point). The remaining 90 patients enrolled (Patients 11-100) will have only 1 whole-body scan, at a time point to be determined based on the results for the first 10 patients. Biopsies are not mandatory, but highly recommended for the scientific purposes of the study. If feasible and the patient consents, all patients will undergo either or both of the following: (a) core biopsy of soft tissue site of disease; (b) core biopsy of bony site of disease. These biopsies will be performed following the last whole-body scan, prior to initiation of a new intervening therapy, and no more than 4 weeks after 89Zr-DFO-huJ591 administration.
Study: NCT03453021

Intervention type: DRUG
Intervention: Mepolizumab
Study: NCT04321616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine will be given orally (in the ICU in gastrointestinal tubes) with 800 mg x 2 loading dose followed by 400 mg x 2 every day for a total of 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine will be given orally (in the ICU in gastrointestinal tubes) with 800 mg x 2 loading dose followed by 400 mg x 2 every day for a total of 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: Remdesivir will be given intravenously 100 mg daily for the duration of the hospitalization and up to 10 days total course. A loading dose of 200 mg at inclusion will be given.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: Remdesivir will be given intravenously 100 mg daily for the duration of the hospitalization and up to 10 days total course. A loading dose of 200 mg at inclusion will be given.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: (Standard of Care) SoC
Description: The standard of care will be supplied to all patients not receiving a drug intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: (Standard of Care) SoC
Description: The standard of care will be supplied to all patients not receiving a drug intervention.
Study: NCT02626169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once a day by mouth for 30 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 90 mg twice daily by mouth for 30 days
Study: NCT03983447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-based intervention to promote PA and reduce ST
Description: This intervention was realized with all the children (1st grade-5th grade) and involved :~1. Physical (Environmental) adaptation of playgrounds~2. Time adaptation of lunch breaks~3. Curriculum-based program for children~4. Workshops and newsletters for parents~5. Meetings for teachers
Study: NCT00775268

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Biopsy taken
Study: NCT00522951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Description: Gadobutrol enhanced MRI (second injection of gadobutrol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProHance
Description: ProHance enhanced MRI (two injections of gadoteridol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)
Study: NCT03696706

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: LED photobiomodulation
Description: LED photobiomodulation will be applied at 36 points, bilaterally, in the temporomandibular joint regions, around these joints, and in the regions of the masseter muscles and anterior part of the temporal muscles, three times a week, totaling 6 treatment sessions, in 2 weeks. The LED apparatus is composed of a flexible rectangular plate (10cm/12cm), which adapts to the format of the area to be treated containing 18 red LEDs - 660 nm and 18 infrared LEDs - 850 nm, with a power of 3.5 mW by LED, 4.45 mW/cm2, radiant exposure of 5.35 J/cm2, radiated area of 14.13 cm2, and energy of 75.6 J.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Placebo LED photobiomodulation
Description: In this group, the same procedures as the LED group will be made, but the device will be turned off.
Study: NCT04000919

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5HTP
Description: 5HTP/carbidopa (50-200 mg 5-HTP/50 mg carbidopa)
Study: NCT03532906

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAP Block
Description: Injection of Bupivacaine 0.5% 20 ml into the thickness of the right abdominal wall and of Bupivacaine 0.5% 10 ml into the surgical wounds.

Intervention type: DRUG
Group type: OTHER
Intervention: Control
Description: Injection of Bupivacaine 0.5% 10 ml into the surgical wounds
Study: NCT01981174

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 30-gauge needle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 32-gauge needle
Study: NCT01211405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose MDMA
Description: 30 mg MDMA administered p.o. once at start of an experimental session. Upon mutual agreement, this may be followed by a supplemental dose of 15 mg MDMA 1.5 to 2 hours later

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medium dose MDMA
Description: 75 mg MDMA administered p.o. once at start of an experimental session. Upon mutual agreement, this may be followed by a supplemental dose of 37.5 mg MDMA 1.5 to 2 hours later
Study: NCT02667288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-101 Solution